Dr. Marc J. Meth, MD
Allergy & Immunology (Clinical & Laboratory Immunology (Allergy & Immunology) Physician)
2080 Century Park E Ste 810
Los Angeles, CA 90067
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Geffen School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 221
Licensed in California since 2008, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of California, Geffen School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical & Laboratory Immunology (Allergy & Immunology) Physician primary
CA license A103999 (first issued 2008; current) · NY license 237973
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Marc J Meth MD Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 221
- Services billed
- 3,369
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 3,203 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 86 |
| Established patient office or other outpatient visit, 20-29 minutes | 126 | 84 |
| New patient office or other outpatient visit, 45-59 minutes | 94 | 94 |
| Test to measure the level of nitric oxide gas | 26 | 21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 19 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 89 payments worth $2,311 in total to this clinician.
| GlaxoSmithKline, LLC. | $465 |
|---|---|
| Novartis Pharmaceuticals Corporation | $368 |
| Regeneron Healthcare Solutions, Inc. | $339 |
| Csl Behring | $247 |
| Genzyme Corporation | $203 |
| Ars Pharmaceuticals Operations, Inc. | $144 |
| Pfizer Inc. | $112 |
| Genentech USA, Inc. | $94.10 |
| Food and Beverage | $2,311 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $759 in research payments for these studies, mostly to the institutions running them.
- Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03428646
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.